secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACCENDRA HEALTH INC/VA/ (ACH)
CIK:        0000075252
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001104659-26-017541
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Accendra Health Q4 revenue $709M; GAAP loss narrows to $9.4M; completes P&HS sale
--------------------------------------------------------------------------------

- Revenue from continuing ops $709M (up 2% YoY); full-year revenue $2.76B (+3% YoY).
- GAAP loss from continuing ops improved to $9.4M from $331.9M in Q4 2024.
- Adjusted net income $16.7M ($0.21/share) vs $25.0M ($0.32) prior year.
- Adj. EBITDA $90M vs $102.5M; free cash flow $18.3M vs $30.1M.
- Completed sale of Products & Healthcare Services on Dec 31, 2025; focusing on cost control and balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/75252/000110465926017541/0001104659-26-017541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/75252/000110465926017541/omi-20260219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-017541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer